An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Phase of Trial: Phase IV
Latest Information Update: 08 Apr 2018
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Roche
- 13 Feb 2018 Planned End Date changed from 28 Feb 2019 to 24 Jun 2020.
- 13 Feb 2018 Planned primary completion date changed from 28 Feb 2019 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated